MedWatch

Financial analyst: Novo Nordisk's obesity treatment could triple market

Jefferies' analysts have consulted with an expert on obesity and diabetes treatments, and now, the investment banking company sees a real possibility that the market for obesity treatment will grow significantly.

Photo: Novo Nordisk / PR

Novo Nordisk's novel weight loss drug Wegovy has the potential to at least double or triple the market, writes investment banking company Jefferies in a report.

The bank has recently hosted a teleconference involving an expert in obesity and diabetes treatment, and the financial analyst bases its estimate on the input from the participating expert.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs